Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | ESR1 | P03372 | 9/20 | 0.58 |
| ▸ | ESR2 | Q92731 | 9/20 | 0.58 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.57 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.57 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.47 |
| ▸ | APP | P05067 | 2/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28572767 | 0.85 | ESR1 (0.56) | LMNACYP1A2MAPTTHRBALOX15 | |
| SCHEMBL30387063 | 0.85 | ESR1 (0.56) | LMNACYP1A2MAPTTHRBALOX15 | |
| SCHEMBL6398262 | 0.79 | MAPT (0.66) | LMNACYP1A2MAPTTHRBALOX15 | |
| SCHEMBL12850681 | 0.79 | LMNA (0.66) | LMNACYP1A2MAPTTHRBALOX15 | |
| SCHEMBL7891196 | 0.77 | MAPT (0.58) | LMNACYP1A2MAPTTHRBALOX15 | |
| SCHEMBL29954485 | 0.77 | MAPT (0.58) | LMNACYP1A2MAPTTHRBALOX15 | |
| SCHEMBL12927715 | 0.77 | MAPT (0.58) | LMNACYP1A2MAPTTHRBALOX15 | |
| SCHEMBL12778281 | 0.76 | ESR1 (0.58) | ESR1ESR2PIK3CAPIK3CBAPP | |
| Zoxazolamine SCHEMBL10891033 | 0.76 | LMNA (1.00) | LMNACYP1A2MAPTTHRBALOX15 | |
| Zoxazolamine SCHEMBL251567 | 0.76 | LMNA (1.00) | LMNACYP1A2MAPTTHRBALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1717230-B1 | FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE | MSD KK (JP) | 2014-08-06 | — | — | EP | disclosed |
| US-8268842-B2 | Fused ring 4-oxopyrimidine derivative | MSD K.K. (JP) | 2012-09-18 | — | — | US | disclosed |
| CN-1918128-B | fused ring 4-oxo-pyrimidine derivatives | BANYU PHARMA CO LTD | 2011-01-26 | — | — | CN | disclosed |
| US-20090209562-A1 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-08-20 | — | — | US | disclosed |
| US-7521455-B2 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO. LTD. (JP) | 2009-04-21 | — | — | US | disclosed |
| CN-1918128-A | Fused ring 4-oxo-pyrimidine derivatives | BANYU PHARMA CO LTD (JP) | 2007-02-21 | — | — | CN | disclosed |
| EP-1717230-A1 | FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-02 | — | — | EP | disclosed |
| US-20050182045-A1 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182045-A1 | Fused ring 4-oxopyrimidine derivative | HRH4, HRH2, HRH3 | LMNA 4856/4885CYP1A2 720/4885MAPT 3669/4885 |
| US-20090209562-A1 | Fused ring 4-oxopyrimidine derivative | HRH4, HRH2, HRH3 | LMNA 4856/4885CYP1A2 720/4885MAPT 3669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.